Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(8 sites)

United States

START San Antonio ( Site 0104), San Antonio, Texas

Israel

Sourasky Medical Center ( Site 1603), Tel Aviv

Russia

Russian Scientific Center of Radiology and Surgical Technologies ( Site 2100), Saint Petersburg, Sankt-Peterburg

South Korea

Samsung Medical Center ( Site 2902), Gangnam, Seoul

Severance Hospital, Yonsei University Health System ( Site 2901), Seodaemun-gu, Seoul

Taiwan

Taipei Veterans General Hospital ( Site 2800), Taipei

Ukraine

ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 2601), Dnipropetrovsk, Dnipropetrovsk Oblast

CNCE Precarpathian Clinical Oncologic Center ( Site 2600), Ivano-Frankivsk, Ivano-Frankivsk Oblast